Guidelines on Diagnosis and Treatment of Malignant Lymphomas
Guidelines on Diagnosis and Treatment of Malignant Lymphomas
Guidelines on Diagnosis and Treatment of Malignant Lymphomas
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
The radioimmunisotope Zevalin is licensed for FL which has<br />
relapsed after Rituximab based treatment resulting in resp<strong>on</strong>se<br />
rates <strong>of</strong> up to 78%. Zevalin has also been used as c<strong>on</strong>solidati<strong>on</strong><br />
after first line treatment <strong>and</strong> prol<strong>on</strong>gs PFS by a median <strong>of</strong> 2 years.<br />
Stem cell transplantati<strong>on</strong><br />
High dose therapy (HDT) with autologous blood stem cell support<br />
(PBSCT) can be c<strong>on</strong>sidered for patients